+86-27-65522453 sales@sun-shinechem.com

Cenicriviroc Mesylate

Catalog No.: S510901
Cas No.: 497223-28-6
Purity : 98% Min.
S510901 - Cenicriviroc Mesylate | CAS 497223-28-6

Catalog number : S510901

CAS number : 497223-28-6

Molecular Formula : C42H56N4O7S2

Molecular Weight : 793.05

Iupac Chemical Name : (S,E)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide, mesylate

Smile : O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4.OS(=O)(C)=O


PackagingPriceAvailabilityPurityEstimated Shipping Time
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsCenicriviroc Mesylate,TAK-652 Mesylate; TBR-652 Mesylate,TAK652,TAK 652
Molecular FormulaC42H56N4O7S2
Molecular Weight793.05
Appearancepale yellow solid
Purity98% Min.
SolubilitySoluble in DMSO, not in water
StorageDry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shipping ConditionShipped under ambient temperature 

Cenicriviroc (CVC) is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH known to cause liver damage and often lead to cirrhosis, liver cancer, or liver failure. Because of this unique mechanism of action, targeting two of the main engines driving NASH, Cenicriviroc (CVC) has the potential to play a differentiated role in the management of adults with liver fibrosis due to NASH and may form the cornerstone of NASH combination treatment strategies, both as a single agent and in combination with other agents targeting metabolic pathways.  Cenicriviroc (CVC) has been granted Fast Track status in adults with liver fibrosis due to NASH, the patient population at highest risk of progression to cirrhosis.

1. Neokosmidis G, Tziomalos K., Role of cenicriviroc in the management of nonalcoholic fatty liver disease.World J Gastroenterol. 2018 Dec 28;24(48):5415-5417. doi: 10.3748/wjg.v24.i48.5415

2. Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L., APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc.Front Immunol. 2018 Aug 8;9:1839. doi: 10.3389/fimmu.2018.01839. eCollection 2018.

3. D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y., Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 Dec;104(6):1241-1252. doi: 10.1002/JLB.5A0817-328RRR. Epub 2018 Aug 8.

497223-28-6 - Request Bulk Quote

497223-28-6 - Request Bulk Quote